Under one in 10 individuals who could benefit from weight-loss injections such as Wegovy are able to get them, states the World Health Organization as it publishes its first guidance on the medications.
Given in excess of 1,000,000,000 individuals worldwide currently obese, it is calling for more widespread and fairer access to these injectable treatments.
According to estimates, in excess of 2,000,000,000 are projected to be obese by 2030 without intervention.
"The latest guidelines recognises that excess weight is a lifelong illness that can be managed with thorough and ongoing treatment," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are major obstacles to widespread access to the jabs that can help people shift substantial body mass, says the organization.
Skinny Jab Shortage
Even under the current best projected case, the production of these medications might only reach around 100 million people – less than 10% of the global need, according to the health organization.
The guideline urges countries and companies to increase access, through strategies like patent sharing.
The intellectual property rights on semaglutide – the primary ingredient of Novo Nordisk's Wegovy – is scheduled to end in several nations in 2026.
The Way Weight-Loss Injections Work
The injections replicate a natural hormone to reduce digestion speed, curb appetite and enhance feelings of fullness so users eat less.
Individuals commonly begin shedding pounds within a few weeks of commencing the regular doses.
Studies indicates patients may regain a significant portion after a year of discontinuing the treatment, because their usual food cravings return.
Being above a healthy weight increases your risk for contracting diseases, including type 2 diabetes, heart disease, brain attack, and specific malignancies.
Obesity concerns people in countries worldwide and was associated with 3.7 million deaths worldwide in 2024, as per the WHO.
